Business
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs, and Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, today announced that they have entered into a collaboration and option agreement. Under this agreement, the companies have agreed t
About this update from Protalix Biotherapeutics, Inc. (de)
[{"type":"text","content":"Partnership combines Protalix's rare disease and biologics expertise with Secarna's AI–powered OligoCreator® platform to jointly develop pharmaceutical candidates for rare renal indications","length":197,"tagName":"p","attribs":{}},{"type":"text","content":"Protalix is granted an exclusive option to license any active compounds derived from the research for potential clinical development and commercialization","length":154,"tagName":"p","attribs":{}},{"type":"text","content":"CARMIEL, Israel and MARTINSRIED, Germany, Dec. 17, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs, and Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, today announced that they have entered into a collaboration and option agreement. Under this agreement, the companies have agreed to partner in the discovery of novel antisense oligonucleotide (ASO) therapies against multiple targets for rare renal indications.","length":716,"tagName":"p"},{"type":"image","alt":"Protalix BioTherapeutics, Inc. Logo","displaySize":"","headline":null,"caption":"Protalix BioTherapeutics, Inc. Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":121,"url":"https://media.zenfs.com/en/prnewswire.com/0aa3562f63cd795a8b943ded1b37e851"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/s4A.QyYWxrkehMY.4ASImg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIxMztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/0aa3562f63cd795a8b943ded1b37e851","width":400,"height":121}}},{"type":"text","content":" ","length":6,"tagName":"p"},{"type":"image","alt":"Secarna Pharmaceuticals Logo","displaySize":"","headline":null,"caption":"Secarna Pharmaceuticals Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":1280,"height":720,"url":"https://media.zenfs.com/en/prnewswire.com/30c16ed91a48751d813efc967cabdd1c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NlEoDDIWmHBqYmkNA_UszQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/30c16ed91a48751d813efc967cabdd1c","width":960,"height":540},"lig...